A replication-defective recombinant adenovirus (Ad) expressing the full length Epstein—Barr virus (EBV) major envelope glycoprotein gp340/220 was tested for its ability to protect against EBV-induced lymphoma in the cottontop tamarin. Antibody responses against Ad capsid proteins and EBV gp340/220 were observed but these antibodies did not neutralize EBV in vitro. However, all immunized animals were protected against challenge following three intramuscular doses of the recombinant Ad. These data indicate that the recombinant Ad is potentially a useful vector for vaccination.
AlkhatibG.,
BriedisD. J.1988; High-level eucaryotic in vitro expression of biologically active measles virus hemagglutinin by using an adenovirus type 5 helper-free vector system. Journal of Virology 62:2718–2727
AttiaM. A.,
WeissD. W.1966; Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumour resistance and enhancement in strain A mice infected with mammary tumour virus. Cancer Research 26:1787–1800
BallayA.,
LevreroM.,
BuendiaM.-A.,
TiollaisP.,
PerricaudetM.1985; In vitro and in vivo synthesis of the hepatitis B surface antigen and of the receptor for polymerised human serum albumin from recombinant human adenovirus. EM BO Journal 4:3861–3865
BejaranoM. T.,
MasucciM. G.,
MorganA. J.,
MoreinB.,
KleinG.,
KleinE.1990; Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. Journal of Virology 64:1398–1401
ChroboczekJ.,
BieberF.,
JacrotB.1992; The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186:280–285
ClearyM. L.,
EpsteinM. A.,
FinertyS.,
DorpmanR. F.,
BornkammG. W.,
KirkwoodJ. K.,
MorganA. J.,
SklarJ.1985; Individual tumors of multifocal EBV induced malignant lymphomas in tamarins arise from different B-cell clones. Science 228:722–724
CooneyE. L.,
CollierA. C.,
GreenbergP. D.,
CoombsR. W.,
ZarlingJ.,
ArdittiD. E.,
HoffmanM. C.,
HuS.-L.,
CoreyL.1991; Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567–572
DavidE. M.,
MorganA. J.1988; Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography. Journal of Immunological Methods 108:231–236
De SchryverA.,
KleinG.,
HewetsonJ.,
RochiG.,
HenléW.,
HenléG.,
MossD.,
PopeJ. H.1974; Comparison of EBV neutralization tests based on abortive infection of transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA). International Journal of Cancer 13:353–362
EloitM.,
Gilardi-HebenstreitP.,
TomaB.,
PerricaudetM.1990; Construction of a defective adenovirus expressing the pseudorabies virus glycoprotein gp50 and its use as a five vaccine. Journal of General Virology 71:2425–2431
EpsteinM. A.,
MorganA. J.,
FinertyS.,
RandleB. J.,
KirkwoodJ. K.1985; Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature, London 318:287–289
EpsteinM. A.,
RandleB. J.,
FinertyS.,
KirkwoodJ. K.1986; Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clinical and Experimental Immunology 63:485–490
GrahamF. L.,
SmileyJ.,
RussellW. C.,
NairnR.1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
GriersonH.,
PurtiloD. T.1987; Epstein-Barr virus infections in males with the X linked lymphoproliferative syndrome. Annals of Internal Medicine 106:538–545
KaselJ. A.1980 Adenoviruses. In Viral, Rickettsial and Chlamydial Infections Edited by
LennetteE.,
SchmidtN.
New York: American Public Health Association;
LeeM. S.,
RoosJ. M.,
McGuiganL. C.,
SmithK. A.,
CormierN.,
CohenL. K.,
RobertsB. E.,
PayneL. G.1992; Molecular attenuation of vaccinia virus: mutant generation and animal characterization. Journal of Virology 66:2617–2630
LoweS. R.,
KellerP. M.,
KeechB. J.,
DavisonA. J.,
WhangY.,
MorganA. J.,
KieffE.,
EllisR.1987; Varicella-zoster virus as a live vector for the expression of foreign genes. Proceedings of the National Academy of Sciences, U. S. A. 84:3896–3900
LubeckM. D.,
DavisA. R.,
ChengalvaM.,
NatukR. J.,
MorinJ. E.,
Molnar-KimberK.,
MassonB. B.,
BhatB. M.,
MizutaniS.,
HungP. P.,
PurcellR. H.1989; Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis vaccine based on live recombinant adenovirus. Proceedings of the National Academy of Sciences, U. S. A. 86:6763–6767
McDermottM. R.,
GrahamF. L.,
HankeT.,
JohnsonD. C.1989; Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169:244–247
MorganA. J.,
NorthJ. R.,
EpsteinM. A.1983; Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form. Journal of General Virology 64:455–460
MorganA. J.,
EpsteinM. A.,
NorthJ. R.1984; Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits and cotton-top tamarins. Journal of Medical Virology 13:281–292
MorganA. J.,
FinertyS.,
LovgrenK.,
ScullionF. T.,
MoreinB.1988a; Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. Journal of General Virology 69:2093–2096
MorganA. J.,
AllisonA. C,
FinertyS.,
ScullionF. T.,
ByarsN. E.,
EpsteinM. A.1989; Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. Journal of Medical Virology 29:74–78
MüllerN.,
EvansA.,
HarrisN. L.,
ComstockG. W.,
JellumE.,
MagnusK.,
OrentreichN.,
PolkB. F.,
VogelmanJ.1989; Hodgkin’s disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. New England Journal of Medicine 320:689–695
MüllerR. E.,
MuldoonR. L.,
JacksonG. G.1969; Communicability of enteric live adenovirus type 4 vaccine in families. Journal of Infectious Diseases 119:60–66
ParkinD. M.,
StjemswardJ.,
MuirC. S.1984; Estimates for the worldwide frequency of twelve major cancers. Bulletin of the World Health Organization 62:163–182
PrevecL.,
SchneiderM.,
RosenthalK. L.,
BelbeckL. W.,
DerbyshireJ. B.,
GrahamF. L.1989; Use of human adenovirus-based vectors for antigen expression in animals. Journal of General Virology 70:429–434 erratum 2539
PrevecL.,
CampbellJ. B.,
ChristieB. S.,
BelbeckL.,
GrahamF.1990; A recombinant human adenovirus vaccine against rabies. Journal of Infectious Diseases 61:27–30
RagotT.,
Tosoni-PittoniE.,
FinertyS.,
MorganA. J.,
PerricaudetM.1990; Recombinant adenoviruses which express the EBV major membrane antigen gp340/220 induce persistent EBV-neutralizing antibodies in rabbits. In Epstein-Barr Virus and Human Disease pp. 231–236 Edited by
AblashiD. V.,
HuangA. T.,
PaganoJ. S.,
PearsonG. R.,
YangC. S.
Clifton, New Jersey: Humana Press;
RagotT.,
EloitM.,
PerricaudetM.1991; Recombinant E1A-defective adenoviruses expressing pseudorabies and Epstein-Barr virus glycoproteins induce immunological response as live vaccines in rabbits and mice. In Human Gene Transfer pp. 249–260 Edited by
Cohen-HaguenauerO.,
BoironM.
London: John Libbey & Co;
SchwartzA. R.,
TogoY.,
HornickR. B.1974; Clinical evaluation of live, oral types 1, 2 and 5 adenovirus vaccines. American Review of Respiratory Disease 109:233–238
TartagliaJ.,
PerkusM. E.,
TaylorJ.,
NortonE. K.,
AudonnetJ.-C.,
CoxW. L,
DavisS. W.,
van der HoevenJ.,
MeignierB.,
RiviereM.,
LanguetB.,
PaolettiE.1992; NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232
TopF. H.Jr,
GrossmanR. A.,
BartelloniP. J.,
SegalH. E.,
DuddingB. A.,
RussellP. K. B.,
scherE. L.1971a; Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. Journal of Infectious Diseases 124:148–154
TopF. H.Jr,
BüscherE. L.,
BancroftW. H.,
RussellP. K.1971b; Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. Journal of Infectious Diseases 124:155–160
WallaceL. E.,
WrightJ.,
UlaetoD. O.,
MorganA. J.,
RickinsonA. B.1991; Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. Journal of Virology 65:3821–3828
WilliamsonJ. D.,
ReithR. W.,
JeffreyL. J.,
ArrandJ. R.,
MackettM.1990; Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. Journal of General Virology 71:2761–2767